Table 1. Association analysis for TTF-1 positivity and clinicopathologic characteristics.
| Characteristic | All patients (n=122) | TTF-1 positive (n=75) | TTF-1 negative (n=47) | P value |
|---|---|---|---|---|
| Age (years) | 0.78a | |||
| Median | 67.0 | 67.0 | 70.0 | |
| Range | 36–82 | 37–82 | 36–80 | |
| Sex | 1.00 | |||
| Female | 34 (27.9) | 21 (28.0) | 13 (27.7) | |
| Male | 88 (72.1) | 54 (72.0) | 34 (72.3) | |
| ECOG PS | 0.19b | |||
| 0 | 42 (34.4) | 25 (33.3) | 17 (36.2) | |
| 1 | 76 (62.3) | 46 (61.3) | 30 (63.8) | |
| 2 | 4 (3.3) | 4 (5.3) | 0 | |
| Smoking history | 0.48 | |||
| Never-smoker | 22 (18.0) | 12 (16.0) | 10 (21.3) | |
| Smoker | 100 (82.0) | 63 (84.0) | 37 (78.7) | |
| Histology | <0.001 | |||
| Adenocarcinoma | 110 (90.2) | 74 (98.7) | 36 (76.6) | |
| Other | 12 (9.8) | 1 (1.3) | 11 (23.4) | |
| PD-L1 TPS | 0.67c | |||
| <1% | 43 (35.2) | 23 (30.7) | 20 (42.6) | |
| 1–49% | 34 (27.9) | 23 (30.7) | 11 (23.4) | |
| ≥50% | 32 (26.2) | 21 (28.0) | 11 (23.4) | |
| Stage | 1.00d | |||
| III | 6 (4.9) | 4 (5.3) | 2 (4.3) | |
| IV | 100 (82.0) | 61 (81.3) | 39 (83.0) | |
| Recurrent | 16 (13.1) | 10 (13.3) | 6 (12.8) | |
| Metastatic site at primary diagnosis | ||||
| Pleura | 45 (36.9) | 30 (40.0) | 15 (31.9) | 0.44 |
| Bone | 40 (32.8) | 25 (33.3) | 15 (31.9) | 1.00 |
| Brain | 28 (23.0) | 20 (26.7) | 8 (17.0) | 0.27 |
| Adrenal gland | 20 (16.4) | 11 (14.7) | 9 (19.1) | 0.62 |
| Liver | 9 (7.4) | 6 (8.0) | 3 (6.4) | 1.00 |
With the exception of age, all data are number (percent). All P values were calculated with Fisher’s exact test. a, <75 vs. ≥75; b, 0 or 1 vs. 2; c, <50% vs. ≥50%; d, III or IV vs. recurrent. ECOG PS, Eastern Cooperative Oncology Group performance status; TTF-1, thyroid transcription factor 1; PD-L1, programmed cell death ligand 1.